Chinese Journal of Clinical Oncology

, Volume 5, Issue 5, pp 387–390

Analysis of the clinicopathologic features and prognosis in triple-negative breast cancer

Article

DOI: 10.1007/s11805-008-0387-6

Cite this article as:
Yang, D., Liu, H. & Zhao, J. Chin. J. Clin. Oncol. (2008) 5: 387. doi:10.1007/s11805-008-0387-6
  • 16 Downloads

Abstract

Objective

To investigate the clinical and pathological features, as well as prognosis in triple-negative breast cancer patients.

Methods

A total of 509 cases of operable breast cancer from January, 2002 to June, 2002 treated in the Cancer Hospital of Tianjin Medical University were analyzed. The Her-2, ER and PR status was determined using immunohistochemistry. Of the total cases, one group was identified as triple negative breast cancer, ie defined as ER, PR and Her-2 negative. The other group was non-triple-negative breast cancer. Clinicopathologic features of the groups were compared and 5-year disease-free survival (DFS) analyzed by the Kaplan-Meier method.

Results

Of the total cases, 21.4% (109/509) of cases were found to be triple-negative while 78.6% (400/509) were non-triple-negative. The triple negative group had higher incidence rates than the non-triple-negative group of the medullary type and Grade III tumors (P < 0.05). There was no other difference in the clinicopathologic features between the 2 groups. From follow-up to June, 2007, 21.1% (23/109) of the triple-negative group and 12.7% (51/400) of the non-triple negative group had a local recurrence or distant metastasis, resulting in a significant difference (P < 0.05). In the triple-negative group and non-triple-negative group, 5-year DFS were 78.9% and 87.3% respectively. There was a statistically significant difference between the 2 groups (P = 0.031).

Conclusion

Compared with non-triple-negative breast cancer, triple-negative breast cancer patients have an increased likehood of a local recurrence or distant metastasis and a poorer prognosis.

Key Words

breast cancer triple negative pathology clinical prognosis 

Copyright information

© Chinese Anti-Cancer Association 2008

Authors and Affiliations

  1. 1.Department of SurgeryTianjin Third Central HospitalTianjinChina
  2. 2.Second Department of Breast Cancer, Key Laboratory for Breast Cancer Prevention and Treatment, Ministry of EducationTianjin Medical University Cancer Institute & HospitalTianjinChina

Personalised recommendations